{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:20:37Z","timestamp":1778840437304,"version":"3.51.4"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense (DOD)","doi-asserted-by":"publisher","award":["W81XWH-12-1-0153"],"award-info":[{"award-number":["W81XWH-12-1-0153"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation (PCF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute (HHMI)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)","doi-asserted-by":"publisher","award":["5U01EB012493"],"award-info":[{"award-number":["5U01EB012493"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences (NIGMS)","doi-asserted-by":"publisher","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund (BWF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MGH-Johnson & Johnson Center for Excellence in CTC Technologies"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood-based biomarkers are critical in metastatic prostate cancer, where characteristic bone metastases are not readily sampled, and they may enable risk stratification in localized disease. We established a sensitive and high-throughput strategy for analyzing prostate circulating tumor cells (CTC) using microfluidic cell enrichment followed by digital quantitation of prostate-derived transcripts. In a prospective study of 27 patients with metastatic castration-resistant prostate cancer treated with first-line abiraterone, pretreatment elevation of the digital CTCM score identifies a high-risk population with poor overall survival (HR = 6.0; P = 0.01) and short radiographic progression-free survival (HR = 3.2; P = 0.046). Expression of HOXB13 in CTCs identifies 6 of 6 patients with \u226412-month survival, with a subset also expressing the ARV7 splice variant. In a second cohort of 34 men with localized prostate cancer, an elevated preoperative CTCL score predicts microscopic dissemination to seminal vesicles and\/or lymph nodes (P &amp;lt; 0.001). Thus, digital quantitation of CTC-specific transcripts enables noninvasive monitoring that may guide treatment selection in both metastatic and localized prostate cancer.<\/jats:p>\n                  <jats:p>Significance: There is an unmet need for biomarkers to guide prostate cancer therapies, for curative treatment of localized cancer and for application of molecularly targeted agents in metastatic disease. Digital quantitation of prostate CTC-derived transcripts in blood specimens is predictive of abiraterone response in metastatic cancer and of early dissemination in localized cancer. Cancer Discov; 8(3); 288\u2013303. \u00a92018 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Heitzer and Speicher, p. 269.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 253<\/jats:p>","DOI":"10.1158\/2159-8290.cd-16-1406","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T20:40:45Z","timestamp":1515098445000},"page":"288-303","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer"],"prefix":"10.1158","volume":"8","author":[{"given":"David T.","family":"Miyamoto","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"2Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kalinich","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"LiCausi","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Chen","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Milner","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Emmons","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uyen","family":"Ho","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Broderick","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Silva","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Javaid","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya Todorova","family":"Kwan","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Hong","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas M.","family":"Dahl","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"5Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"McGovern","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"5Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"2Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lecia V.","family":"Sequist","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Kapur","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Lee","family":"Wu","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"6Department of Pathology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Stott","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."},{"name":"7Center for Engineering in Medicine, Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Ting","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Toner","sequence":"additional","affiliation":[{"name":"7Center for Engineering in Medicine, Massachusetts General Hospital, Boston, Massachusetts."},{"name":"8Department of Surgery, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamala","family":"Maheswaran","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"8Department of Surgery, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Haber","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."},{"name":"9Howard Hughes Medical Institute, Chevy Chase, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2022060700591277200_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrclinonc.2013.30","article-title":"Validation and clinical utility of prostate cancer biomarkers","volume":"10","author":"Scher","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060700591277200_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Armstrong","year":"2012","journal-title":"Eur Urol"},{"key":"2022060700591277200_bib3","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022060700591277200_bib4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"2022060700591277200_bib5","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib6","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060700591277200_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2014.82","article-title":"Circulating tumour cells-monitoring treatment response in prostate cancer","volume":"11","author":"Miyamoto","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060700591277200_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022060700591277200_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/2159-8290.CD-12-0222","article-title":"Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer","volume":"2","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov"},{"key":"2022060700591277200_bib10","first-page":"178","article-title":"Decoding the androgen receptor splice variants","volume":"2","author":"Lu","year":"2013","journal-title":"Transl Androl Urol"},{"key":"2022060700591277200_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science"},{"key":"2022060700591277200_bib12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022060700591277200_bib14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022060700591277200_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"2022060700591277200_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"2022060700591277200_bib17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"2022060700591277200_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0090-4295(01)01441-8","article-title":"Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium","volume":"58","author":"Partin","year":"2001","journal-title":"Urology"},{"key":"2022060700591277200_bib20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","article-title":"A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer","volume":"90","author":"Kattan","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2022060700591277200_bib21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"2022060700591277200_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","article-title":"Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer","volume":"194","author":"Dinh","year":"2015","journal-title":"J Urol"},{"key":"2022060700591277200_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijrobp.2015.01.051","article-title":"Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy gleason score and PSA: a population-based study of modern patients","volume":"92","author":"Caster","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060700591277200_bib24","doi-asserted-by":"crossref","first-page":"25ra3","DOI":"10.1126\/scitranslmed.3000403","article-title":"Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer","volume":"2","author":"Stott","year":"2010","journal-title":"Sci Transl Med"},{"key":"2022060700591277200_bib25","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.juro.2008.01.102","article-title":"Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer","volume":"179","author":"Davis","year":"2008","journal-title":"J Urol"},{"key":"2022060700591277200_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.urolonc.2015.12.003","article-title":"Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"Urol Oncol"},{"key":"2022060700591277200_bib27","doi-asserted-by":"crossref","first-page":"179ra47","DOI":"10.1126\/scitranslmed.3005616","article-title":"Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells","volume":"5","author":"Ozkumur","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022060700591277200_bib28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1073\/pnas.1617032114","article-title":"An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma","volume":"114","author":"Kalinich","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700591277200_bib29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"2022060700591277200_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13073-015-0252-1","article-title":"Landscape of gene fusions in epithelial cancers: seq and ye shall find","volume":"7","author":"Kumar-Sinha","year":"2015","journal-title":"Genome Med"},{"key":"2022060700591277200_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1078-0432.CCR-16-0237","article-title":"Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer","volume":"23","author":"Saylor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022060700591277200_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib33","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060700591277200_bib34","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00432-014-1775-3","article-title":"Circulating tumor cell detection in high-risk non-metastatic prostate cancer","volume":"140","author":"Loh","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022060700591277200_bib35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"The Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"2022060700591277200_bib36","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700591277200_bib37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"key":"2022060700591277200_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2016.07.021","article-title":"Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer","volume":"71","author":"Bernemann","year":"2017","journal-title":"Eur Urol"},{"key":"2022060700591277200_bib40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2022060700591277200_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21606-5","volume-title":"The elements of statistical learning","author":"Hastie","year":"2001"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/3\/288\/1839182\/288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/3\/288\/1839182\/288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:59:38Z","timestamp":1654549178000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/3\/288\/6229\/An-RNA-Based-Digital-Circulating-Tumor-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1406","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22531927.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531924.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531927","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546586","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546586.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}